Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T14:17:06.055Z.
Calculation as of: 2026-10-06T14:17:06.055Z.
Quote observation: 2026-10-06T14:14:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4b900084dfad819c514917b73a3910c9d2e92354b8183d11bfa5ab73513aed11
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
SeaStar Medical Holding Corporation
Market Cap
$9.22M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$9.04M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$8.51M
Price/OCF Ratio
N/A
TTM Avg
9.84
3Y Avg
9.84
5Y Avg
9.84
Market Cap
$10.27M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SeaStar Medical Holding Corporation (ICU) | $9.22M | N/A | N/A | N/A | N/A |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $9.04M | N/A | N/A | N/A | N/A |
| Jasper Therapeutics, Inc. (JSPR)vs › | $9.48M | N/A | N/A | N/A | N/A |
| Ainos, Inc. (AIMD)vs › | $9.76M | N/A | N/A | N/A | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.51M | N/A | 9.84 | 9.84 | 9.84 |
| DataMEDS AI, Inc. (MEDS)vs › | $8.42M | N/A | N/A | N/A | N/A |
| MetaVia Inc. (MTVA)vs › | $10.03M | N/A | N/A | N/A | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.29M | N/A | N/A | N/A | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.27M | N/A | N/A | N/A | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $10.66M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
